Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis
Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.)...
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
PAGEPress Publications
2011-09-01
|
| 丛编: | Reumatismo |
| 在线阅读: | http://www.reumatismo.org/index.php/reuma/article/view/293 |